Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Withdraws Prexige In Australia Ahead Of FDA Decision Due To Deaths

This article was originally published in The Pink Sheet Daily

Executive Summary

Withdrawal of the COX-2 inhibitor in Australia following two deaths from liver injury is likely to impact the outcome of FDA’s review.

You may also be interested in...



Ouch, Canada! Prexige Withdrawn From Yet Another Market

Ottawa withdraws marketing authorization for Novartis’ troubled anti-inflammatory drug due to the potential for serious liver damage.

Ouch, Canada! Prexige Withdrawn From Yet Another Market

Ottawa withdraws marketing authorization for Novartis’ troubled anti-inflammatory drug due to the potential for serious liver damage.

No Big Surprise For Novartis: Prexige Is “Not Approvable” At FDA

Firm now plans to discuss path forward, which may include additional trials of the COX-2 inhibitor, with FDA, Novartis tells "The Pink Sheet" DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel